Recurrent Breast Cancer Terminated Phase 2 Trials for Everolimus (DB01590)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02273752Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTreatment